Tanei Takafumi, Yamamoto Shun, Maesawa Satoshi, Nishimura Yusuke, Ishizaki Tomotaka, Nagashima Yoshitaka, Ito Yoshiki, Hashida Miki, Suzuki Takahiro, Hamasaki Hajime, Wakabayashi Toshihiko, Saito Ryuta
Department of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan.
Department of Specialized Headache Outpatient, Nagoya Garden Clinic, Nagoya 451-0051, Japan.
Neurol Int. 2025 Apr 22;17(5):62. doi: 10.3390/neurolint17050062.
: Lasmiditan is a newly developed drug for the acute treatment of migraine attacks, but factors associated with its efficacy remain unclear. This study aimed to confirm the efficacy of lasmiditan started at 50 mg under various dosing conditions and identify factors associated with its efficacy. : There are four reasons for prescribing lasmiditan: as an add-on to triptan, if triptan is ineffective, if triptan produces side effects, and when triptan is contraindicated. Lasmiditan was administered at a dose of 50 mg. The efficacy of lasmiditan was defined as the disappearance of headache or a 50% or greater reduction in headache intensity within two hours after dosing. This study included 108 patients with migraines who took lasmiditan. : The results for efficacy and the side effects of lasmiditan were as follows: effective without side effects (22), effective with mild side effects (32), ineffective (14), and severe side effects (40). The efficacy rate of lasmiditan 50 mg was 50.0% (54/108). The following factors were found to be associated with lasmiditan's efficacy: sex, migraine classification, calcium channel blockers, and anti-calcitonin gene-related peptide monoclonal antibody (CGRP-mAb) treatment. The overall incidence of side effects was 66.7%, and the dropout rate was 37.0%. Somnolence was more prevalent in the effective group, and other side effects were more prevalent in patients who dropped out due to the side effects of lasmiditan. : Lasmiditan is likely to be effective in males with severe migraine classification and receiving CGRP-mAb treatment. If mild somnolence is a side effect, the drug can be continued and may be effective.
拉米地坦是一种新开发的用于急性治疗偏头痛发作的药物，但其疗效相关因素仍不清楚。本研究旨在确认50毫克起始剂量的拉米地坦在各种给药条件下的疗效，并确定与其疗效相关的因素。：开具拉米地坦有四个原因：作为曲坦类药物的附加用药、曲坦类药物无效时、曲坦类药物产生副作用时以及曲坦类药物禁忌时。拉米地坦的给药剂量为50毫克。拉米地坦的疗效定义为给药后两小时内头痛消失或头痛强度减轻50%或更多。本研究纳入了108名服用拉米地坦的偏头痛患者。：拉米地坦的疗效和副作用结果如下：无副作用有效（22例）、有轻度副作用有效（32例）、无效（14例）和有严重副作用（40例）。50毫克拉米地坦的有效率为50.0%（54/108）。发现以下因素与拉米地坦的疗效相关：性别、偏头痛分类、钙通道阻滞剂和抗降钙素基因相关肽单克隆抗体（CGRP - mAb）治疗。副作用的总发生率为66.7%，脱落率为37.0%。嗜睡在有效组中更常见，其他副作用在因拉米地坦副作用而脱落的患者中更常见。：拉米地坦可能对重度偏头痛分类且接受CGRP - mAb治疗的男性有效。如果轻度嗜睡是一种副作用，可以继续使用该药物，且可能有效。
